Atrasentan Hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective antagonist of the endothelin-A (ETA) receptor, atrasentan binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
Atrasentan belongs to a pyrrolidine and benzodioxole derivative. It is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in the inhibition of endothelin-induced angiogenesis and tumor cell proliferation. Its potential therapeutic uses include the treatment of diabetic nephropathies and as an antineoplastic agent.
Atrasentan is a selective endothelin ETA receptor antagonist with an IC50 of 0.2 nM for ETA compared to 190 nM for ETB receptors. It blocks blocks endothelin induced cell proliferation, and has been investigated as a possible treatment for prostate cancer, and more recently for therapy for diabetic kidney disease.
